Together, these findings show that combined BCL-XL and CDK1/2/4 targeting, while perturbing cell cycle regulators, leads to a combinatorial depletion of survival and RTK/AKT signals, restoring FOXO3a tumour suppression actions. The gene discussed is CDK1; the disease is neoplasm.